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Immunogenicity of anthrax 
recombinant peptides and killed 
spores in goats and protective 
efficacy of immune sera in A/J 
mouse model
Okechukwu C. Ndumnego  1,3, Susanne M. Koehler2,4, Jannie E. Crafford1, Wolfgang Beyer2 & 
Henriette van Heerden1
Anthrax is primarily recognized as an affliction of herbivores with incubation period ranging from three 
to five days post-infection. Currently, the Sterne live-spore vaccine is the only vaccine approved for 
control of the disease in susceptible animals. While largely effective, the Sterne vaccine has several 
problems including adverse reactions in sensitive species, ineffectiveness in active outbreaks and 
incompatibility with antibiotics. These can be surmounted with the advent of recombinant peptides 
(non-living) next generation vaccines. The candidate vaccine antigens comprised of recombinant 
protective antigen (PA), spore-specific antigen (bacillus collagen-like protein of anthracis, BclA) 
and formaldehyde inactivated spores (FIS). Presently, little information exists on the protectivity 
of these novel vaccine candidates in susceptible ruminants. Thus, this study sought to assess the 
immunogenicity of these vaccine candidates in goats and evaluate their protectivity using an in vivo 
mouse model. Goats receiving a combination of PA, BclA and FIS yielded the highest antibody and 
toxin neutralizing titres compared to recombinant peptides alone. This was also reflected in the passive 
immunization experiment whereby mice receiving immune sera from goats vaccinated with the antigen 
combination had higher survival post-challenge. In conclusion, the current data indicate promising 
potential for further development of non-living anthrax vaccines in ruminants.
Anthrax, a disease widely recognized as a primary disease of ruminants1, is caused by the Gram-positive, aerobic, 
spore-forming bacterium Bacillus anthracis. In nature the disease is mainly transmitted to susceptible herbivores 
by viable dormant spores present in contaminated foliage and soils. It progresses as a hyperacute infection in 
ruminants following an incubation period of three-five days2. The main virulence factors are encoded by two 
plasmids; pXO1, which codes for the three toxin components of protective antigen (PA), lethal factor (LF) and 
edema factor (EF)3–5 whereas pXO2 encodes the anti-phagocytic poly-ɣ-D-glutamic acid capsule (PDGA)6. The 
full virulence of B. anthracis depends on the existence of both plasmids. PA bonds with LF, forming lethal toxin 
(LT), a zinc metalloprotease that inactivates several mitogen-activated protein kinase kinases (MAPKK) leading 
to impairment and death of susceptible macrophages and other immunocompetent cells7,8. Edema toxin (ET) 
is a calmodulin dependent adenylate cyclase formed by the combination of PA to EF and which catalyses the 
production of cyclic AMP from the host ATP leading to the disruption of fluidic homeostasis in the host cells9,10.
The poorly immunogenic PDGA facilitates the dissemination of B. anthracis in the body of infected animals11. 
Masking of anthrax bacilli by the PDGA capsule enables it to avoid immune surveillance mechanisms and to 
proliferate systemically once inside the circulatory system12,13. Research has linked the PDGA with LT in the 
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blood of experimentally infected animals14 and this was shown to significantly enhance the deleterious effects of 
LT in mice15.
The Sterne live spore vaccine is currently the only vaccine of choice for the control of anthrax in domestic 
animals. It is an attenuated pXO1+, pXO2− strain (34F2)16 known to induce good levels of immunity without 
clinical signs of the disease. However, some of the limitations of this vaccine include possible adverse reactions in 
some sensitive species17–19, short term protection20, ineffectiveness in active outbreaks and incompatibility with 
antibiotics21,22. Thus, the development of an alternative vaccine that can be produced quickly in the face of an 
anthrax outbreak, safe to administer and compatible with antibiotics is invaluable.
Induction of antibodies against PA is the main immune response following vaccination of animals with the 
Sterne live spore vaccine23–25. The anti-PA antibodies prevent the development of lethal intoxication and is vital 
for protection against germinating virulent anthrax bacilli26. Adding other anthrax antigens to PA-based vaccine 
candidates has been reported to improve the protection afforded to laboratory animals challenged with virulent 
anthrax spores27. An ideal non-living recombinant protein-based anthrax vaccine should be able to induce broad 
spectrum immunity targeting both toxaemia and bacteraemia. In the current study, an acellular vaccine formu-
lation comprising of recombinant PA (rPA) and two other antigens; Bacillus collagen-like protein of anthracis 
(rBclA) and formaldehyde inactivated spores (FIS) were administered in a goat model and the resulting immune 
response and protection evaluated. BclA is an immunodominant glycoprotein found on the surface of the B. 
anthracis exosporium28,29, Previously, the addition of BclA to PA constructs had offered superior protection 
against virulent challenge in mice30,31 while FIS with PA-based vaccines significantly augmented the protection 
afforded to mice and guinea pigs32,33. We assessed the antibody response to rPA, rBclA, FIS and a lipopeptide 
adjuvant following vaccination in goats. The adjuvant comprised of N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R, 
S)-propyl]-(R)-cysteinyl-seryl-(lysyl)3-lysine (Pam3Cys-SK4), a potent TLR2/1 activator admixed to Pam3Cys 
conjugated to FISEAIIHVLHSRHPG, a T-helper cell epitope from the sperm whale myoglobin34–36. We have pre-
viously shown that 70% of NMRI mice vaccinated with a combination of PA, BclA and lipopeptide adjuvant were 
protected against virulent challenge with B. anthracis Ames strain spores37. The adjuvant is well-defined, superior 
to conventional preparations and shows no untoward effects in animals38.
Results
Humoral immune response to non-living anthrax antigens in goats. Five goats each were vacci-
nated subcutaneously with rPA + rBclA+ lipopeptide adjuvant or rPA + rBclA + FIS+ lipopeptide adjuvant on 
weeks 0, 3 and 6. The jugular blood of each animal was sampled before each vaccination and again on week 10. 
Goats vaccinated twice with the Sterne live spore vaccine and vaccine diluent served as controls. Prepared sera 
were tested for IgG against PA, BclA, whole spores and lethal toxin neutralizing ability. Mean IgG titres against 
PA rose significantly after the first vaccination with rPA + rBclA + FIS+ lipopeptide adjuvant (P = 0.023) and 
increased after the second vaccination (Table 1). Significant changes in levels of anti-PA IgG were observed after 
the second vaccination with rPA + rBclA+ lipopeptide adjuvant. The highest increases in titres were observed 
after a second vaccination with either of the antigen combinations. A third vaccination only effected marginal 
changes in the recorded titres. The pre-challenge titres were equivalent with those observed following vaccina-
tions with the Sterne live spore vaccine (Fig. 1).
A significant increase of anti-BclA IgG was observed in goats vaccinated with rPA + rBclA and 
rPA + rBclA + FIS (P ≤ 0.031) after the first vaccination. Generally, the anti-BclA titres were a log lower 
than anti-PA titres after the second or third vaccination (Table 1). These antibodies were insignificant in 
the Sterne-vaccinated goats throughout the trials (Fig. 2). Conversely, the anti-spore IgG response in the 
Sterne-vaccinated group was higher when compared with any of the groups vaccinated with the non-living vac-
cine candidates (P ≤ 0.002), though also significantly elevated in the FIS-containing group (Fig. 3). While pro-
duction of anti-spore IgG was evident following the first vaccination with rPA + rBclA + FIS, none was observed 
throughout the study in the rPA + rBclA-vaccinated animals (Table 1 and Fig. 3).
The development of significant lethal toxin neutralizing antibodies was only seen after the second vaccina-
tion with either of the non-living vaccine combinations (Table 1). Thereafter it followed the pattern as seen with 
Vaccine group
Pre-
vaccination Week 3 Week 6  Week 10
rPA + rBclA
Anti-PA IgG 2.41 ± 0.37 2.87 ± 0.55 4.44 ± 0.23*** 4.14 ± 0.36***
Anti-BclA IgG 2.42 ± 0.30 2.85 ± 0.22* 3.28 ± 0.19** 3.19 ± 0.24***
Anti-spore IgG 0.71 ± 1.20 0.35 ± 0.98 1.07 ± 1.22 0.68 ± 1.16
TNAc n.d. 0.37 ± 1.04 2.95 ± 0.25*** 2.79 ± 0.54***
rPA + rBclA + FIS
Anti-PA IgG 2.09 ± 0.22 2.59 ± 0.33* 3.91 ± 0.38*** 4.27 ± 0.37***
Anti-BclA IgG 2.06 ± 0.14 2.51 ± 0.23* 3.10 ± 0.35** 3.19 ± 0.48**
Anti-spore IgG 1.16 ± 1.31 3.05 ± 0.42* 3.32 ± 0.23* 2.99 ± 0.18*
TNAc n.d. 0.34 ± 0.95 2.61 ± 0.33*** 2.92 ± 0.47***
Table 1. Antibody titresab (log10) of goats vaccinated on weeks 0, 3 and 6 with recombinant proteins 
(rPA + rBclA) and lipopeptide adjuvant or recombinant proteins, inactivated spores and lipopeptide adjuvant 
(rPA + rBclA + FIS). aMean log10 titres ± 95% confidence interval. bTitres were compared to the respective pre-
vaccination titres (*P < 0.05; **P < 0.005; ***P < 0.0005). cLethal toxin neutralization titres rPA; Recombinant 
protective antigen 83. rBclA; Recombinant bacillus collagen-like protein of anthracis. FIS; Formaldehyde 
inactivated spore. n.d; Not detected.
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anti-PA IgG titres but at a lower level. There was no difference in the TNA titres after the second or third vacci-
nation (P ≥ 0.152). Following the stabilization of the neutralizing antibody levels after the second vaccination, 
the titres remained steady till the end of the experiment and were equivalent to the Sterne-vaccinated controls 
(Fig. 4).
Protection conferred on A/J mice by caprine immune sera. To assess the protective efficacy of the 
immune response generated by vaccination of goats with anthrax recombinant proteins and inactivated spores, a 
Figure 1. Individual anti- protective antigen (PA) IgG titres in goats (with mean bars and SD). The animals 
were either vaccinated thrice with rPA+rBclA (n =5) and rPA+rBclA+FIS (n =5) on weeks 0, 3 and 6 (sera 
collected for analyses on week 10) in combination with lipopeptide adjuvant or twice with Sterne live spore 
(n = 5) on weeks 0 and 12 (sera collected for analyses on week 17). The naïve controls (n = 3) received the 
vaccine diluent. IgG titres of each group were compared to the respective pre-immune titres (**P < 0.005; 
***P < 0.0005). rPA; Recombinant protective antigen 83rBclA; Recombinant bacillus collagen-like protein of 
anthracisFIS; Formaldehyde inactivated spore.
Figure 2. Individual anti-BclA IgG titres in goats (with mean bars and SD). The animals were either vaccinated 
thrice with rPA+rBclA (n = 5) and rPA+rBclA+FIS (n = 5) together with lipopeptide adjuvant on weeks 
0, 3 and 6 (sera collected for analyses on week 10) or twice with Sterne live spore (n = 5) on weeks 0 and 12 
(sera collected for analyses on week 17). The naïve controls (n = 5) received the vaccine diluent. IgG titres 
of each group were compared to the respective pre-immune titres (*P < 0.05; **P < 0.005; ***P < 0.0005).
rPA; Recombinant protective antigen 83rBclA; Recombinant bacillus collagen-like protein of anthracisFIS; 
Formaldehyde inactivated spore.
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Figure 3. Individual anti-spore IgG titres in goats (with mean bars and SD). The animals were either vaccinated 
thrice with rPA+rBclA (n = 5) and rPA+rBclA+FIS (n = 5) together with lipopeptide adjuvant on weeks 
0, 3 and 6 (sera collected for analyses on week 10) or twice with Sterne live spore (n = 5) on weeks 0 and 12 
(sera collected for analyses on week 17). The naïve controls (n = 5) received the vaccine diluent. IgG titres 
of each group were compared to the respective pre-immune titres (*P < 0.05; **P < 0.005; ***P < 0.0005).
rPA; Recombinant protective antigen 83rBclA; Recombinant bacillus collagen-like protein of anthracisFIS; 
Formaldehyde inactivated spore.
Figure 4. Individual anthrax lethal toxin neutralization titres in goats (with mean bars and SD). The animals 
were either vaccinated thrice with rPA+rBclA (n = 5) and rPA+rBclA+FIS (n = 5) with lipopeptide adjuvant 
on weeks 0, 3 and 6 (sera collected for analyses on week 10) or twice with Sterne live spore (n = 5) on weeks 
0 and 12 (sera collected for analyses on week 17). The naïve controls (n = 3) received the vaccine diluent. IgG 
titres of each group were compared to the respective pre-immune titres (***P < 0.0005). rPA; Recombinant 
protective antigen 83rBclA; Recombinant bacillus collagen-like protein of anthracisFIS; Formaldehyde 
inactivated spore.
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passive in vivo mouse protection experiment was carried out after adoptive caprine sera transfer. Following lethal 
challenge with ~1.92 × 105 Sterne 34F2 B. anthracis spores, sera from naïve goats failed to protect the susceptible 
mice with all the challenged mice dying within 3 days (Fig. 5). Sera from rPA + rBclA-vaccinated goats protected 
68% of the challenged mice and 73% were protected by rPA + rBclA + FIS immune sera. Sera from the Sterne 
vaccinates protected 87% of challenged A/J mice. Analysis of the survival data from the groups showed no differ-
ence in survival between the rPA + rBclA, rPA + rBclA + FIS and Sterne vaccinated groups (P ≥ 0.189). On the 
other hand, these groups showed increased survival times compared to the naïve (negative) controls (P < 0.001).
To ascertain if there is any association between the measured antibody titres and survival against anthrax in 
the A/J mice, a Pearson’s correlation study was performed. This revealed a strong positive relationship between 
anti-PA, anti-spore and toxin neutralizing antibody titres and survival in the mice (Table 2). There was no signif-
icant correlative association between anti-BclA IgG titres and survival in the challenged mice.
Discussion
In addition to performing the trials in this study under more controlled conditions, evaluation of the protective 
capacity of immune sera was performed using an in vivo mouse challenge model. This model has been used previ-
ously albeit in homogenous mouse sera transfer39 or adoptive heterogenous immune sera transfer from Sterne live 
spore vaccinates20. To the best of our knowledge, this study represents the first attempt to assess a recombinant 
anthrax vaccine candidate in a ruminant model using a passive mice protection model. Immune sera from goats 
vaccinated with combinations of rPa + rBclA + FIS and rPA + rBclA were able to protect 73% and 68% of A/J 
mice from lethal anthrax challenge respectively. Immune titres peaked following a single booster vaccination with 
the non-living vaccine candidates, indicating the expendability of a second booster vaccination.
Anthrax is chiefly a disease of herbivorous animals with ruminants being most susceptible1,2. The disease is 
largely controlled using the Sterne live spore vaccine which is an unencapsulated but toxinogenic strain40,41. The 
vaccine retains some residual virulence, though attenuated and has limited effectiveness in the face of an active 
anthrax outbreak22,42. With the advent of multicomponent recombinant anthrax antigens capable of stimulating 
broad spectrum immune response in vaccinates, questions have risen about the potential usefulness of such 
vaccine candidates in the control of the disease in livestock. While the antigens of B. anthracis rPA, rBclA and 
FIS, alone or in combination are recognized for their protective efficacy from many laboratory rodent studies27, it 
remains to be elucidated if these antigens will elicit a similar response in a ruminant model of anthrax infection. 
Figure 5. Passive protection of A/J mice following in vivo transfer of immune sera from goats and lethal 
challenge with ~1.92 × 105 Sterne 34F2 spores. The rPA+rBclA+FIS (n = 11) and rPA+rBclA (n = 19) groups 
with lipopeptide adjuvant received sera from goats vaccinated thrice with the respective vaccine candidates 
(also see Table 1). The Sterne live spore group (n = 15) sera were collected from goats vaccinated twice with 
Sterne strain spores. Naive (n = 9) sera were from goats injected with vaccine diluent (saline). *** denotes 
significantly increased survival as compared to the negative control (P < 0.001). There was no difference 
between the survival times of the Sterne live spore, rPA+rBclA+FIS and rPA+rBclA vaccinated groups 
(P ≥ 0.189). rPA; Recombinant protective antigen 83rBclA; Recombinant bacillus collagen-like protein of 






Survival Pearson Correlation 0.460** 0.357** 0.336* 0.251
Significance (2-tailed) <0.001 0.008 0.013 0.067
Table 2. Pearson’s correlation analysis of relationship between survival times of passively challenged A/J mice 
and caprine sera antibody titres. aLethal toxin neutralization titres. *Correlation is significant at the 0.05 level 
(2-tailed). **Correlation is significant at the 0.01 level (2-tailed).
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Recently, we tested a combination of rPA and rBclA with or without FIS in a mixed breed of farm goats, under 
field conditions43. In spite of low lethal toxin neutralizing titres, measured at point of lethal challenge, 80% of 
goats receiving rPA, rBclA and FIS were protected from direct lethal challenge with B. anthracis spores43.
PA is responsible for the production of toxin neutralizing antibodies which is vital for protection against 
anthrax infections26,44. It is the principal immunogen of the licensed human vaccine45 and forms the primary 
component of numerous recombinant anthrax candidate vaccines. The measure of anti-PA and toxin neutraliz-
ing antibodies peaked after a second vaccination with either of rPA + rBclA or rPA + rBclA + FIS and lipopep-
tide adjuvant. This was also replicated in the production of anti-BclA and anti-spore (rPA + rBclA + FIS only) 
antibodies. The results indicated that these recombinant vaccines were able to induce strong immune responses 
comparable to the Sterne live spore vaccinated controls. The humoral response to BclA in the Sterne vaccinated 
controls was poor, which was noted previously24. Previous studies in mice37 and rabbits (unpublished data) had 
recorded antibody titres against the BclA used in this study. Notwithstanding, almost 90% of challenged mice 
were protected by Sterne vaccinates sera implying the insignificant role of anti-BclA antibodies in protection 
against anthrax in these animals, a fact also observed in the direct challenge of Sterne vaccinated goats24. The 
addition of FIS to the rPA + rBclA vaccine combination increased survival (not significant) by 5% (Fig. 5). In an 
earlier study using similar vaccine candidates, 50% of goats vaccinated with rPA + rBclA were protected against 
direct virulent B. anthracis spores challenge compared to 80% survival observed in rPA + rBclA + FIS-vaccinated 
goats43. Though not significant, more mice were protected by the FIS, BclA and PA vaccinates’ sera compared to 
PA and BclA alone (Fig. 5). A correlative study of the association between antibody titres and survival reinforced 
this assumption with anti-PA, anti-spore and toxin neutralization titres showing positive correlations (Table 3). 
A possible optimal combination of possible vaccine candidates (for future trials) based on our results will be a PA 
and FIS vaccine with the addition of an adjuvant. Not only will this combination be less complex, but also poten-
tially easier to mass produce. A similar PA and FIS vaccine combination was shown to afford better protection in 
mice and guinea pig models previously32,33.
Except for the anti-spore response, there was little difference in the humoral response of the recombinant 
vaccinated animals. The in vivo A/J mouse protection model evaluates the level of protection afforded by induced 
humoral antibodies following vaccination20,39,46. In this model, the toxin-neutralizing efficacy of these antibodies 
in protection of the susceptible A/J mice against lethal challenge with B. anthracis Sterne strain (toxin+ cap-
sule−)47 is critical. The ~70% protection observed following vaccination with rPA + rBclA and rPA + rBclA + FIS 
in this study demonstrates the potential protective capacity in the donor animal. The lipopeptide adjuvant used 
in this study, Pam3Cys-SK4 represents a highly efficient immunoadjuvant used in peptide/protein vaccination 
(Mittenbuhler et al. 2003). Pam3Cys-SK4 has been reported severally to enhance the humoral immune response to 
antigens in various species38,48–51. Co-administration of the adjuvant with the recombinant proteins was well tol-
erated by the goat hosts throughout the trials. The choice of 500 µl as the volume of passively transferred immune 
sera was based on previous studies20,39 and after consultations with PCB Turnbull. The adverse reactions in some 
of the mice following intraperitoneal serum transfer were unexpected. The post mortem reports on the affected 
mice indicated possible anaphylactic reactions (serum sickness) due to the serum infusion (not shown). This may 
have been dependent on the individual immune status of the mice affected as repetitions with the same volume 
of serum did not result in further deaths. On hindsight, the use of affinity-purified antibodies from immune sera 
could have prevented these reactions.
In summary, our study reveals the potential of a non-living anthrax vaccine in inducing a protective immune 
response in vaccinated goats. Results indicate the protective capacity induced in caprine sera following vaccina-
tion with either rPA + rBclA or rPA + rBclA + FIS in combination with a lipopeptide adjuvant.
Materials and Methods
Preparation and purification of recombinant proteins and Bacillus anthracis spores. Escherichia 
coli BL21-CodonPlus-RIL cells (Stratagen, LaJolla, USA) retaining the plasmid pREP4 (Qiagen, Venlo, 
Netherlands) and pQE-30 (Qiagen, Venlo, Netherlands) that encodes either rPA83 or rBclA were cultured and 
refined as previously described24,52. Proteins used for ELISA received no further treatment whilst proteins for 
vaccination were tested for endotoxin using the Limulus Amoebocyte Lysate Endochrome-K test kit (Charles 
River, Wilmington, USA) as described by the manufacturer. Endotoxin removal was carried out via EndoTrap 
blue endotoxin removal system (Hyglos, Bernried, Germany).






Number of Mice  
(in vivo challenge)
rPA + rBclA × 3 5 rPA = 75 µg/dose rBclA = 75 µg/dose Lipopeptide adjuvant = 500 µg/dose 0, 3, 6 19
†
rPA + rBclA + FIS × 3 5 (3)*
rPA = 75 µg/dose rBclA = 75 µg/dose 
FIS = 108 spores/dose Lipopeptide 
adjuvant = 500 µg/dose
0, 3, 6 11†
Negative (naive) × 1 3 1 mL of vaccine diluent 0 9 (3 mice tested/goat)
Positive × 2 5 Goats vaccinated twice with 1 mL Sterne live spore vaccine 0, 12 15 (3 mice tested/goat)
Table 3. Vaccine group designations, dosage and schedule. †Some mice reacted adversely from in vivo goat 
serum transfer and either died or were euthanized. *Sera of three goats assessed by in vivo challenge due to 
adverse reactions in mice. rPA; Recombinant protective antigen 83. rBclA; Recombinant bacillus collagen-like 
protein of anthracis. FIS; Formaldehyde inactivated spore.
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The FIS suspension from Sterne vaccine strain (34F2) done as previously53 with some modifications. Spores 
were incubated at 37 °C overnight in PBS at concentrations containing at least 109 spores/mL and formaldehyde at 
a final concentration of 4% formalin. Subsequently, after pelleting at 4000 × g for 15 min (room temperature), the 
spores were washed four times with PBS in 0.1% gelatine. This was followed by resuspension in PBS and storage at 
−80 °C. Aliquots of the FIS suspension was tested for sterilization by streaking on blood agar after treatment with 
histidine (to neutralize any remnant formalin).
B. anthracis 34F2 Sterne spores (batch no. 86) utilized for goat immunization and in vivo mouse challenge 
were sourced from Onderstepoort Biological Products (OBP, Onderstepoort, South Africa). The spores were 
prepared by the dilution and centrifugation of the spores with sterile PBS/glycerin (0.1%) solution at 3000 × g 
for 15 min at 4 °C. The final spore suspension was treated at 65 °C for 30 min in a water bath before counting and 
storage at 4 °C in sterile PBS/glycerine solution.
Immunization experiments and passive protection tests. Goats were screened for PA-reactive anti-
bodies using the conventional PA ELISA. Following arrival and acclimatization at the OBP experimental animal 
facility, the goats were randomly allocated to designated vaccine groups and immunized as indicated in Table 3. 
A/J mice (Jackson Laboratories, Bar Harbor, USA) were procured for the in vivo challenge study performed at 
the University of Pretoria Biomedical Research Centre (UPBRC), South Africa. The A/J mouse strain is deficient 
in the C5 complement component which renders it vulnerable to infection by vaccine-strain Sterne spores54,55. 
These mice develop lethal systemic anthrax following infection with Sterne spores in the absence of protective 
antibodies20,25,39. Experiments with animals were conducted in accordance with ethical principles and guidelines 
provided by the animal use and care committees of the UPBRC, OBP and University of Pretoria respectively 
(Protocol number V065/12). Section 20, Act 35 of 1984 permission was granted by the Directorate of Animal 
Health, Department of Agriculture, Forestry and Fisheries, South Africa (registration number 12/11/1/1/6).
For the passive protection tests, sera (500 µl) from vaccinated goats and controls (naive and hyperimmune 
goats) were injected intraperitoneally into naïve A/J mice. Following the transfer of caprine sera into the A/J 
mice, lethal challenge was performed 24 h later with B. anthracis Sterne strain. In the experimental design, a total 
of 5 mice per goat serum (for the protein-vaccinated groups) and 3 mice per serum [for the Sterne-vaccinated 
(positive) and naïve (negative) controls] were used. However, due to the unexpected adverse reactions shown by 
some of the mice following the adoptive transfer of sera and subsequent exclusion from the trials, the challenge 
experiment was performed with reduced mice number for some of the serum samples (Table 3). In rPA + rBclA 
group, two goat immune sera were tested with five mice each while sera from three goats were assessed with 
four, three and two mice respectively (19 mice in total). Two caprine sera were assessed with five mice each in 
rPA + rBclA + FIS group and a serum sample was tested with one mouse (three sera samples were assessed in this 
group, 11 in total). Consequently, the challenge and survival data were pooled for each vaccine group.
Measurement of serum IgG titres. Sera were analysed for specific immunoglobulins using ELISA as pre-
viously described by52 with some modifications. Individual wells of 96-well microtitre plates (Nunc immuno-
plate Maxisorp, Germany) were coated with 0.5 µg of antigen (or 107 FIS) in bicarbonate buffer and incubated 
overnight at 4 °C. The plates were washed twice with PBS containing 0.05% Tween (PBST) using a Biorad PW40 
washer (Mamesla-Coquette, France) and blocked in 200 µL PBST containing 5% skimmed milk powder (PBSTM) 
and incubated for 1 h at room temperature (RT). The plates were washed twice, and the test sera and controls 
diluted in PBSTM. A two-fold dilution (starting dilution; 1:50) was made across the plates in duplicates and incu-
bated for 30 min on a rotatory shaker (Titretek® flow labs, UK). Following incubation, the plates were washed 5 
times and 100 µL of horseradish peroxidase-conjugated rabbit anti-goat IgG (Invitrogen, Camarillo, USA) diluted 
to 1:4000 in PBSTM was added to every well and incubated for 30 min on the plate shaker. After washing 5 times, 
the plates were developed with 2,2′ azino bis (3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt (Sigma, 
Germany) and absorbance readings taken at 405 nm using a Biotek powerwave XS2 reader (Winooski, USA). 
Endpoint titres of individual serum were defined as the reciprocal of the highest serum dilution giving an optical 
density of 0.1. Titres of <50 were ascribed an arbitrary value of 0.
Toxin neutralization assay (TNA). An in vitro toxin neutralizing assay (TNA) was carried out with 
J774A.1 mouse macrophage cell line (ECACC cat no 91051511) as done previously with modifications24,56. The 
96-well flat-bottomed tissue culture plates (Greiner bio one, Germany) seeded with 80 000 macrophages per 
well in Dulbecco’s modified eagle media (DMEM) and 10% foetal calf serum (FCS) were incubated overnight at 
37 °C and 5% CO2. Test sera were diluted 2-fold (starting dilution; 1:50) in culture medium with PA and LF (List 
Biological Laboratories Inc., Campbell, USA) at concentrations of 500 ng/mL and 400 ng/mL respectively. The 
serum/lethal toxin mixture was incubated for 1 h at 37 °C and 5% CO2 before addition to overnight-cultured cells 
and incubation for 3 h. Every serum sample was tested in duplicates. Subsequently, addition of 25 µL of 5 mg/mL 
MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Invitrogen, USA) per well and incubation 
in the dark at 37 °C and 5% CO2 was performed. Two hours after incubation, cells were lysed with pre-warmed 
(37 °C) acidified isopropyl alcohol (90% isopropyl alcohol, 0.5% SDS, 25 mM HCl) by vigorously pipetting up and 
down to solubilize the formazan dye.
Finally, plates were rested for 5 min and the absorbance read at 540 nm with a Biotek power wave XS2 reader. 
Each assay included a single dilution series of positive control serum from a goat hyper-immunized with the 
Sterne live spore vaccine serving as a positive control and for assay reproducibility. Three wells in each assay 
receiving LT served as blanks, another triplicate of wells (with cells) received only LT as toxin control while only 
culture media was placed in two wells (medium control). The neutralization of each serum sample was calculated 
using the formula:
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= − ÷ − ×NT sample toxin control medium control toxin control( ) ( ) 10050
Neutralization titres (NT50) were expressed as the reciprocal of the highest serum dilution at which the mac-
rophage survival yielded 50% and obtained using the Gen5 data analysis software (Biotek Instruments, USA).
Statistics. For determination of ELISA and TNA titres, 4-parametre logistic regression curves were gener-
ated from serial dilution data using the Gen 5 data analysis software (Biotek Instruments, Winooski, USA). Data 
obtained were log-transformed and variance equality were tested with the Levene’s tests (IBM SPSS Statistics 
23). Antibody titre differences between groups at particular time points were analysed using unpaired student 
t-test, with a two-tailed P-value. Baseline and pre-challenge ELISA and TNA data within vaccine groups were 
compared using a paired Student’s t test. Kaplan-Meier (product limit estimation) plots were used to compute the 
mean survival times of challenged mice (pooled per treatment group). Survival curves were compared between 
each treatment group and controls using the Mantel-Cox (Log Rank) test. The strength of association between the 
survival time following lethal challenge and specific immune titres was measured using the Pearson’s correlation 
coefficient. Results having a p value of ≤ 0.05 were considered statistically significance.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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